Table 3 Therapeutic decisions for hetMNA patients with localised, INSS 4s and 4 (<12 months) tumour stages

	No CTX	Conventional dose CTX	High-dose CTX with stem cell reinfusion
Stage 1	10¹	3^2,3	—
Relapse	0	0	—
DOD/DOT	0	0	—
Stage 2	5¹	4²	5²
Relapse	2	0	0
DOD/DOT	1 DOD^ugb,^a	0	1 DOT^fgb
Stage 3	—	6¹	15²
Relapse	—	2	2
DOD/DOT/D	—	1 DOD^ugb	1 DOD^ugb, 1 D
Stage 4s	1¹	1¹	2²
Relapse	1	0	0
DOD/DOT	1 DOD^ugb,b	0	0
Stage 4 <12 m	—	1¹	2²
Relapse	—	0	0
DOD/DOT	—	0	0
Stage unknown	1¹	—	—
Relapse	0	—	—
DOD/DOT	0	—	—
Total	17	15	24
Relapse	3	2	2
DOD/DOT	2 DOD	1 DOD	1 DOD, 1 DOT, 1 D

Fifty six patients with localised stages, stage 4s or stage 4 (<12 months at diagnosis) tumours are categorised according to therapeutic decisions into three treatment groups: no cytotoxic therapy (CTX), conventional CTX, or high-dose CTX for high-risk neuroblastoma (NB) patients
Four patients received cytotoxic treatment; however, information on the exact regimen was lacking: 1 stage 2, 2 stage 3 (no relapses), 1 stage 4s (relapse, patient alive). All three patients with localised stages who died of disease were >18 months of age at diagnosis and had an unfavourable genomic background tumour. The hetMNA patient who died OWING to toxicity was <18 months at diagnosis and had a tumour with only numeric chromosomal aberrations
CTX chemotherapy, DOD dead of disease, DOT death due to toxicity, D death not tumour-related, HR high risk, INSS International Neuroblastoma Staging System, fgb favourable genomic background tumour, ugb unfavourable genomic background tumour
Upgrading of risk according to the MYCN status (hetMNA): ¹no upgrading, ²upgrading, ³two patients were treated according to LINES G9 (low and intermediate risk neuroblastoma treatment group 9 for stage 1 neuroblastomas with MYCN amplification)
^aNo MNA in the relapse material
^bhomMNA in the relapse material

Quick links

Search